CASC2 and neoplasm: The expression level of onco-lncRNAs, including PCAT19, MALAT1, and NEAT1, and the tumor suppressor lncRNA, CASC2, was increased and decreased, respectively, in PCa patients compared to the healthy group (P < 0.05) (Table 4).